Adhoc: MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

July 21, 2017 12:30 PM

Phase II Trial of Investigational Anetumab Ravtansine Did Not Meet Primary Endpoint in Patients With Advanced Pleural Mesothelioma PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 21, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its partner, Bayer AG, has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural...

Read more

MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

July 21, 2017 12:23 PM

Phase II Trial of Investigational Anetumab Ravtansine Did Not Meet Primary Endpoint in Patients With Advanced Pleural Mesothelioma PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 21, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its partner, Bayer AG, has reported that a phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent...

Read more

MorphoSys Announces that Its Licensee, Janssen, Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

July 13, 2017 5:24 PM

First Antibody Generated from MorphoSys's HuCAL Library Technology to Receive Marketing Approval PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 13, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its licensee, Janssen Biotech, Inc. ("Janssen"), has reported that the U.S. Food and Drug Administration ("FDA") has approved Tremfya™ (guselkumab) for the treatment of...

Read more

MorphoSys Celebrates 25th Anniversary

July 6, 2017 12:15 PM

Head of the Bavarian State Chancellery Honors Entrepreneurial Achievements PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 6, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY, XETRA: MOR), one of the premier biotechnology companies in Germany, is celebrating its 25th company anniversary today. At a ceremony with approximately 500 guests from business and politics, as well as employees of the Munich/Germany-based...

Read more

Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement

July 3, 2017 6:00 AM

Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need Concurrent financing of $15.7 million from Acer investor syndicate Acer plans to file a NDA for its lead product, EDSIVO™, for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018 CAMBRIDGE, MA / THE WOODLANDS, TX /...

Read more

BASi Names Dr. Gregory C. Davis to Board of Directors

June 20, 2017 8:38 AM

WEST LAFAYETTE, IN / ACCESSWIRE / June 20, 2017 / Bioanalytical Systems, Inc. (NASDAQ: BASI) ("BASi" or the "Company") today announced that the board of directors unanimously elected Dr. Gregory C. Davis as a director effective June 14, 2017. This action brings the number of directors to four. Larry Boulet, BASi's Chairman of the Board, commented, "We are delighted that Dr. Davis has joined our board. His strong background in the...

Read more

MyDx Launches Canadian National Marketing Campaign to Promote Transparency and Prevent Abuse with Its CannaDx Cannabis Handheld Chemical Analyzer

June 15, 2017 3:10 PM

Multi Six Figure Campaign to Leverage Premium Television, Radio, Billboard and Print Media Across Canada SAN DIEGO, CA / ACCESSWIRE / June 15, 2017 / MyDx, Inc. (OTCQB: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for the Cannabis professional and retail consumer to correlate the chemical profile of cannabis with the consumers reporting of its...

Read more

Kane Biotech Inc. to Present at The MicroCap Conference on June 27th in Toronto at the Sheraton Centre Hotel

June 12, 2017 11:53 AM

TORONTO, ON / ACCESSWIRE / June 12, 2017 / Kane Biotech Inc. (TSX-V: KNE, OTC PINK: KNBIF) will be presenting at this year's MicroCap Conference on June 27th in Toronto. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various...

Read more

MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at ASCO 2017

June 5, 2017 9:30 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / June 5, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) today presented updated safety and efficacy data from an ongoing phase 1/2a study of the anti-CD38 antibody MOR202 at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD)...

Read more

MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL

June 5, 2017 9:25 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / June 5, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) today presented safety and efficacy data from an ongoing phase 2 clinical trial ("L-MIND" study) evaluating MOR208 in combination with lenalidomide in patients with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL). DLBCL is the most common form of non-Hodgkin's lymphoma. Data were reported during a...

Read more

MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL

June 2, 2017 1:55 AM

First pivotal study with compound from MorphoSys's proprietary portfolio started, following IDMC recommendation after initial safety evaluation PLANEGG/MUNICH, GERMANY / ACCESSWIRE / June 2, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the pivotal phase 3 part of the B-MIND clinical study of MOR208 has been opened for enrollment. The randomized, multicenter phase 2/3 study is designed to...

Read more

Molecular Partners Provides Additional Details on Clinical Studies of Proprietary Lead Oncology Asset MP0250

May 30, 2017 1:02 AM

- First Patient Dosed in Phase 2 Multiple Myeloma Study - IND Submission to FDA in H2 2017 Planned for MP0250 in EGFR-Mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC) ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 30, 2017 / Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple...

Read more

MorphoSys Announces That Its Licensee Janssen Reported Updates on the Development of Guselkumab

May 24, 2017 6:10 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 24, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen), has provided an update on the development of guselkumab. Guselkumab is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated by MorphoSys utilizing its proprietary HuCAL antibody library technology. According...

Read more

MorphoSys to Present at Three Upcoming Conferences

May 24, 2017 2:00 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 24, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: MorphoSys Investor & Analyst Event at ASCO 2017: Date: June 5, 2017, 6:30 p.m. CDT (June 6, 2016, 0:30 a.m. BST, 1:30 a.m. CEST) Venue: Chicago, IL, USA Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG Dr. Malte Peters, Chief Development Officer of...

Read more

MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers

May 19, 2017 2:00 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the completion of the first part of a phase 1 clinical study in healthy volunteers with the investigational drug candidate MOR107 ahead of schedule. MOR107 is a selective agonist of the angiotensin II receptor type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology platform of MorphoSys's...

Read more

American Cryostem Retains Target Health To Initiate FDA Drug Master Files And 510K Approvals

May 18, 2017 8:00 AM

EATONTOWN, NJ / ACCESSWIRE / May 18, 2017 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the engagement of Target Health Inc. (Target), New York, NY, to assist the Company with the filing of a Drug Master File (DMF) to support its ongoing efforts for...

Read more

MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017

May 18, 2017 2:00 AM

Updates on Hemato-Oncological Programs MOR208 and MOR202 will be presented PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the publication of four abstracts accepted for the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago, Illinois, USA. The abstracts include first data from the phase 2 "L-MIND"...

Read more

MorphoSys AG Reports Outcome of Annual General Meeting 2017

May 17, 2017 9:00 AM

All Resolutions Proposed by the Company's Management Approved PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 17, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that its shareholders approved all resolutions proposed by the Company's Management at the Company's Annual General Meeting which took place on Wednesday, 17 May 2017, including: - The discharge of the members of the Management and...

Read more

BacTech Reports Consistent High Grades From Telamayu Drilling

May 8, 2017 1:45 PM

Averages 12 oz/t Silver and 1.73% Tin Over 10 Meters TORONTO, ON / ACCESSWIRE / May 8, 2017 / BacTech Environmental Corporation ("BacTech" or the "Company"), (CSE: BAC, OTC PINK: BCCEF) today announced assays for an additional 10 holes drilled at the Telamayu, Bolivia tailings project. 60 holes were drilled in total. Additional results will be released as they become available. Highlights of the latest analyses include continued strong silver...

Read more

Cultivation Technologies, Inc. Launches Genetic Improvement Program for Medical Cannabis; Led by Two Biotech Experts with 70 Years Combined Experience

May 8, 2017 6:00 AM

IRVINE, CA / ACCESSWIRE / May 8, 2017 / Cultivation Technologies, Inc. ("CTI"), a leader in medical Cannabis infrastructure, science, and branding, announced today that it has formed a specialized Plant Molecular Breeding group which will utilize modern genomic tools to unlock the medical potential of Cannabis. For thousands of years, Cannabis has been regarded as a plant with numerous beneficial applications, yet the genetic and biochemical...

Read more